In multiple myeloma, deletion of chromosome 13 (del (13)) is associated with poor prognosis regardless of treatment. This study analyzed the impact of del(13) status on response and survival following treatment with either bortezomib or highdose dexamethasone in patients in the SUMMIT and APEX trials. Additionally, matched-pairs subset analyses were conducted of patients with and without del(13), balanced for age and International Staging System parameters. In both SUMMIT and APEX, prognosis appeared to be poorer in bortezomibtreated patients with del(13) compared with patients with no del(13) by metaphase cytogenetics. In the SUMMIT and APEX matched-pairs analysis, response and survival appeared comparable in bortezomib-treated patients with or without del (13) by metaphase cytogenetics. However, patients with del(13) receiving dexamethasone in APEX appeared to have markedly decreased survival compared with those without del(13) by metaphase cytogenetics. These matched-pairs analyses suggest that bortezomib may overcome some of the poor impact of del(13) as an independent prognostic factor. However, sample sizes were very small; these findings require confirmation from further studies. Leukemia (2007) 21, 151-157.
Introduction
Deletion of chromosome 13 (del(13)), as detected by conventional cytogenetics or fluorescence in situ hybridization (FISH), has been associated with poor prognosis in multiple myeloma. This adverse prognostic impact has been independent of treatment approach, including chemotherapy, 1,2 high-dose therapy with single or tandem autotransplantation [3] [4] [5] [6] [7] or miniallogeneic transplantation. 8 In 79 newly diagnosed multiple myeloma patients treated with chemotherapy, overall survival (OS) was inferior in patients with del(13) compared with those with no del(13) (10 versus 35 months).
2 Del(13) was detected in 16% of patients by conventional cytogenetics and was associated with reduced 5-year event-free survival (EFS) and OS in 1000 multiple myeloma patients receiving melphalanbased high-dose therapy and autotransplantation. 3 In 427 newly diagnosed or previously treated multiple myeloma patients receiving tandem transplantation, an unfavorable karyotype including del (13) was associated with inferior EFS and OS. 7 Finally, in 68 patients with mostly advanced myeloma treated with mini-allogeneic transplantation, those with del (13) , as detected by FISH, had shorter EFS and OS, and higher relapse rates than patients with no del (13) . 8 These and other 1, 4, 5, [9] [10] [11] studies have found an association between del(13), by conventional cytogenetics or FISH, and poor prognosis. Of note, the adverse prognostic impact of del (13) has been reported to be more pronounced when detected by metaphase cytogenetics than when detected by FISH. 1, 12, 13 Bortezomib is a specific and reversible inhibitor of the 26S proteasome, binding to the chymotrypsin-like enzymatic site. 14 The incomplete and transient inhibition of the ubiquitinproteasome pathway results in apoptosis of myeloma cells, whereas sparing the normal tissue.
14 Bortezomib is the first proteasome inhibitor to be approved in the United States for the treatment of relapsed multiple myeloma. In the phase 2 SUMMIT 15 and CREST 16 trials, bortezomib alone and in combination with dexamethasone demonstrated activity in patients with relapsed and/or refractory multiple myeloma. In the randomized, phase 3 APEX trial, bortezomib demonstrated superiority over high-dose dexamethasone in response rates, time to progression and OS in 669 patients with multiple myeloma following 1-3 prior therapies. 17 Our objective was to assess the impact of the presence of del (13) , identified by either metaphase cytogenetics or FISH, on response rate and survival in phase 2 (SUMMIT) and phase 3 (APEX) clinical trials of bortezomib.
Materials and methods
The SUMMIT and APEX trials were conducted in accordance with the Declaration of Helsinki principles. All patients in these multi-institutional trials provided written informed consent, and all participating centers obtained review board approval as published previously. 15, 17 In SUMMIT, a total of 202 patients with relapsed and refractory multiple myeloma were treated with bortezomib 1.3 mg/m 2 twice weekly for 2 weeks for up to eight 3-week cycles. Dexamethasone 20 mg could be added on the day of and the day after each bortezomib dose to patients with progressive disease after two cycles or stable disease after the first four cycles. The primary end point was response rate to bortezomib. Secondary end points included time to progression and survival. Del (13) , including monosomy and deletion, was detected by metaphase cytogenetics or FISH. The objective of this analysis was to evaluate the impact of del(13) on survival in patients with known del(13) status. Additionally, a subset matched-pairs analysis was conducted of patients with and without del (13) by metaphase cytogenetics, balanced for patient age (p65 versus 465 years) and International Staging System (ISS) 18 parameters. Each patient with del(13) was matched with one patient without del (13) .
In APEX, a total of 669 patients with relapsed multiple myeloma were randomized to receive bortezomib 1.3 mg/m 2 twice weekly for 2 weeks for eight 3-week cycles followed by once weekly for 4 weeks for three 5-week cycles (n ¼ 333) or high-dose dexamethasone 40 mg on days 1-4, 9-12 and 17-20 for four 5-week cycles followed by days 1-4 of up to five 4-week cycles (n ¼ 336). The primary end point was time to progression. Secondary end points included response rate and survival. Del (13) , including monosomy and deletion, was again detected by metaphase cytogenetics or FISH. As in SUMMIT, the objective of this analysis was to evaluate the impact of del (13) on survival in patients with known del(13) status. Similarly, matched-pairs analyses of patients with and without del(13) by metaphase cytogenetics and FISH were conducted in both the bortezomib and dexamethasone arms. These matched-pairs analyses were balanced for adverse prognostic variables, including number of lines of prior therapy (one line versus more than one line), patient age and ISS parameters. 18 Each patient with del(13) by metaphase cytogenetics was matched with a maximum of two patients without del(13) by metaphase cytogenetics; each patient with del(13) by FISH was matched with one patient without del(13) by FISH.
In both SUMMIT and APEX, all patients were to have a bone marrow aspirate and biopsy at screening. It was requested but not mandated that the aspirate be sent for cytogenetic study at the local institution, although the method (metaphase cytogenetics or FISH) was not specified. Cytogenetic results were reviewed independently by two physicians to assess the presence of del (13) .
Results

SUMMIT
Of 202 patients enrolled in SUMMIT, 37 patients were evaluated by FISH and 147 patients by metaphase cytogenetics for del(13) status ( Figure 1a ). By FISH, del(13) was detected in only three of 37 patients, and so these data were not used in our analysis. By metaphase cytogenetics, del(13) was detected in 26 of 147 patients. Patients with del(13) appeared to have a poorer prognosis, although differences in response rate and median OS were not statistically significant in patients with or without del(13) ( Table 1 ). These patients also had a higher median b 2 -microglobulin (b 2 M) level and a higher proportion of patients aged 465 years. Similarly, in a matched-pairs analysis comparing the 26 patients with del(13) versus 26 patients without del (13) , response rate and median OS ( Figure 2 ) appeared similar in patients with or without del(13) ( Table 1) .
APEX
Of 669 patients enrolled in APEX, 246 patients were evaluated by FISH or metaphase cytogenetics for del (13) Del (13) was detected in 24 of 168 patients by metaphase cytogenetics. In patients with known del(13) status by metaphase cytogenetics, median OS was lower in patients with del (13) in both treatment arms with the difference being more pronounced in the dexamethasone arm (Table 1) , although there was no significant difference in response rates. Again, median b 2 M level was higher in patients with del(13) compared with those without del (13) in both treatment arms (Table 1) .
In a matched-pairs analysis comparing 21 of these del(13) patients with 41 patients with no del(13); del(13) status by metaphase cytogenetics did not appear to be associated with a significant difference in response rates in both treatment arms (Table 1) . However, survival was significantly poorer among dexamethasone-treated patients with del(13) compared with no del(13) (P ¼ 0.002; Figure 3a) , whereas in bortezomib-treated patients, del(13) status did not appear to be associated with a difference in survival (P ¼ not significant; Figure 3b ).
Del (13) was detected in 40 of 138 patients by FISH. In a matched-pairs analysis comparing 38 patients with del(13) with 38 patients with no del(13) by FISH, del(13) status was not associated with statistically significant differences in response rate or median survival (all data not reached) in either treatment arm (Table 1) .
Discussion
Del (13) has been associated with poor prognosis in patients with multiple myeloma regardless of treatment modality when detected by both metaphase cytogenetics, a conventional method for detection of chromosomal abnormalities, and FISH, a newer and more sensitive method for detection of del (13) that is commonly used in clinical practice. 19 This adverse prognostic impact appears to be related to the increased bone marrow microvessel density 20 and proliferative indices of myeloma cells 11, 21, 22 in patients with del(13) compared with those without. However, the adverse prognostic impact of del (13) has been less pronounced when detected by FISH than when detected by conventional metaphase cytogenetics 1,12,13 and may be related to the potentially greater association between elevated plasma cell proliferation and del(13) detected by metaphase cytogenetics (compared with del(13) detected by FISH), 1, 13 or to a high false-positive rate with FISH. 23 Indeed, in a recent review, Stewart and Fonseca 19 highlight that the net effect on prognosis of del (13) is greatest when del(13) is detected by conventional cytogenetics, compared with FISH, and recommend that all multiple myeloma patients be screened for del(13) using conventional cytogenetics.
FISH has resulted in higher detection rates for del(13) compared with conventional cytogenetics (33-54 versus 14-27%). [1] [2] [3] [4] 8, 10, 11 Using metaphase cytogenetics, 17.7 and 14.3% of evaluable patients showed del(13) in SUMMIT and APEX, respectively, rates that are similar to those obtained in previous trials with this technique. As expected, del(13) was detected in a higher percentage (29.0%) of evaluable patients in APEX using FISH.
In our analyses of all patients with known del(13) status by metaphase cytogenetics (unmatched for other prognostic factors) in the SUMMIT (bortezomib alone or in combination with dexamethasone in patients with suboptimal response to monotherapy) and APEX (bortezomib monotherapy versus high-dose dexamethasone) trials, patients with del(13) appeared to have a slightly poorer prognosis, although the difference was not significant in SUMMIT, and was more pronounced in the dexamethasone arm in APEX. It should be noted that the Bortezomib in chromosome 13 deletion S Jagannath et al baseline characteristics of del(13) patients in these analyses differ substantially from those without the deletion, and thus the contribution of these factors to the outcomes cannot be ruled out. Our matched-pairs analyses were designed with this in mind so we could reduce the potential bias by balancing patient age (p65 versus 465 years), ISS parameters and, in APEX, the number of lines of prior therapy.
The results of these matched-pairs subset analyses of the SUMMIT and APEX trials suggest that there is no clear survival advantage for patients with no del (13) and bortezomib may overcome some of the poor impact associated with del(13) as an independent prognostic factor; del(13) by conventional metaphase cytogenetics was not associated with a significant reduction in survival in myeloma patients receiving bortezomib. In contrast, survival of del(13) patients was significantly poorer for the dexamethasone arm in the APEX trial. Consistent with a previous report, 19 our FISH analysis did not detect significant del(13) associated differences in either arm of the APEX trial, despite del(13) by conventional cytogenetics being associated with inferior survival in the dexamethasone arm. This is possibly owing to the lesser effect on prognosis of del (13) by FISH. It should be noted that other studies have failed to show an association between response rate and del(13) by FISH. 1, 8 However, it is difficult to draw firm conclusions regarding the statistical significance or otherwise of the results of the present analysis owing to the very small numbers of patients in the matched-pairs subsets. These findings require confirming in larger studies specifically examining the impact of del (13) status.
Nonetheless, the suggestion that bortezomib may overcome some of the adverse prognostic impact of del (13) in terms of survival is supported by other studies. 24, 25 Proteasome inhibitors were found to induce antiproliferative and proapoptotic activity in patient-derived multiple myeloma cell lines, irrespective of del(13) status. 25 Furthermore, in a study of patients with advanced multiple myeloma, bortezomib in combination with dexamethasone produced responses that were independent of del (13) . 24 Overall, 11 of 15 (73%) patients achieved a complete (CR) or partial response (PR), including eight of 10 (80%) patients with del(13) by FISH or metaphase cytogenetics.
Results, presented at the 2005 Annual Meeting of the American Society of Hematology, of a phase 2 trial of patients with relapsed/refractory multiple myeloma also suggest that Table 1 Patient characteristics, response rate, time to progression and OS for all patients with known del(13) status and the matched-pairs subsets in the SUMMIT and APEX populations of patients with del (13) Of the 24 patients with del(13) by metaphase cytogenetics, only 21 patients had at least one corresponding match in the no del(13) population. c Forty-one patients were identified in the no del(13) population instead of 42 patients because in one instance a grouping of two del(13) patients could only be matched to a three-patient grouping in the no del(13) population.
induction of response with bortezomib is independent of chromosomal abnormalities such as del (13) treatment failure and survival following bortezomib treatment appeared shorter in patients with del(13) compared with those without del (13) , these groups were not matched for other factors resulting in poorer survival, including serum albumin level and level of bone marrow plasma cells, and concomitant amplification of CKS1B (1q21) also resulted in shortened survival in some patients with del (13) . Notably, there was no difference in survival between responding patients with del(13) and those without (P ¼ 0.48); the short median survival in del(13) patients was due to rapid progression of non-responders.
A recently published trial assessing bortezomib in combination with melphalan and prednisone (bortezomib (Velcade) þ Melphalan þ Prednisone (VMP)) as front-line therapy in elderly patients indicated that VMP appears to overcome the poor prognosis conferred by del (13) . All patients with del (13) responded, and response rates, EFS and progression-free survival were similar among patients with and without del (13) . 26 Results of a randomized phase 3 trial of 668 patients with previously untreated multiple myeloma showed that addition of thalidomide to Total Therapy 2 improved CR rate and EFS but not OS. 27 However, in the one-third of patients with chromosomal abnormalities including del (13) , the probability of EFS and OS was significantly lower. Bortezomib has been incorporated into Total Therapy 3 in a trial that has accrued 247 of a target 300 patients with newly diagnosed multiple myeloma. Preliminary results show an improved CR rate compared with Total Therapy 2, with a cumulative CR and nCR rate of 80 versus 69% at 18 months (P ¼ 0.01) (Barlogie et al., J Clin Oncol, 2006; 24: 426s; Abstract 7519).
Another strategy that may potentially overcome the adverse prognostic impact of del(13) involves early allogeneic transplantation followed by donor lymphocyte infusions. 28, 29 In a subset of patients that developed acute or chronic graft-versusmyeloma alloreactivity, del (13) had no impact on outcome. On the other hand, myeloma patients with del(13) who were treated with interferon a2 had significantly inferior OS compared with those not treated with interferon a2.
1 Interestingly, interferon a2 therapy had no impact on survival in patients without del (13) . The investigators hypothesized that the inferior outcome with interferon a2 in patients with del(13) may be related to the antiapoptotic effects of this cytokine in myeloma cells, but acknowledged that the mechanism needed to be further elucidated.
In conclusion, bortezomib appears to be an appropriate therapeutic strategy for a broad set of myeloma patients, including patients with del (13) . Given the limited number of patients analyzed in this paper, further studies are clearly warranted to better evaluate the prognostic relevance of del (13) in bortezomib-treatment patients. To this end, a phase 2 investigation is underway in patients with newly diagnosed high-risk multiple myeloma sponsored by the National Cancer Institute and the Eastern Cooperative Oncology Group (Dispenzieri et al., Blood, 2005; 106: 715a; Abstract 2546). In a multivariate analysis of patients enrolled in SUMMIT, response to bortezomib was independent of sex, race, performance status, isotype, del (13) , prior therapy, hemoglobin, or b 2 M level. 30 Only patient age X65 years and bone marrow plasma cell infiltration 450% were associated with a significant decrease in response to bortezomib, and thus far, there has been no identified adverse prognostic factor that bortezomib has been unable to at least partially overcome. These findings have been largely confirmed in a prospective analysis in the phase 3 APEX trial, which demonstrated the advantage of bortezomib versus high-dose dexamethasone in response rate, time to progression and survival regardless of patient age, b 2 M level, number of prior therapies or refractoriness to last prior therapy (Richardson et al., J Clin Oncol, 2005; 23: 568s; Abstract 6533).
